Rational combined antibacterial therapy of the first line for treatment of patients with in-patient community-acquired pneumonia
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Abstract
Given that community-acquired pneumonia (CAP) is a frequent disease, in which antibiotics are always prescribed, in foreign literature there are papers devoted to rationalizing of the choice of one-component or combination antibiotic therapy (ABT) in this pathology, as well as to optimize its terms appointment.
The objective: to evaluate the efficacy, safety and rationality of the appointment of beta-lactam in combination with azithromycin (Chemomycin® from the manufacturer Hemofarm AD, Serbia) in patients with CAP of the third clinical group.
Materials and methods. The study was attended by 25 patients the third clinical group of CAP, who were treated in the therapeutic and pulmonary departments of the city. After diagnosis, the patient was given a combined ABT: beta-lactam, namely, amoxicillin / clavulanate (at a dose of 1,2 g three times a day intravenously) or ceftriaxone (at a dose of 2 g once a day intravenously), and the macrolide, namely the preparation of azithromycin Chemomycin® from the manufacturer Hemofarm AD, Serbia (at a dose of 500 mg once daily orally).
Results. As a result, all patients included in the study, found recovery. In the treatment of patients, there were no apparent clinical side effects of the drug. In addition, in patients with the presence of concomitant cardiology, the deterioration of the condition, the appearance of new changes and/or prolongation of the QT interval (clinically and according to the electrocardiogram) was not observed in any case.
Conclusion. 1. The presence of a frequent concomitant pathology and false habits in hospitalized patients with CAP of our region is a risk factor for the presence of intracellular pathogens, as well as typical strains of respiratory pathogens producing beta-lactamase; this is an indication for the addition of macrolides (mainly azithromycin) to the first line ABT that acts on intracellular pathogens and destroys the Haemophilus influenzae biofilms.
2. Integrated step-by-step antibiotics inpatients with CAP in the three-day oral azithromycin treatment program (Chemomycin®) significantly reduces the serum level of the systemic inflammation marker of CRP, is safe and highly effective.
3. The drug Chemomycin® is well tolerated, it can be recommended as a drug of choice for conducting a complex first-line ABT for the patients with third clinical group of CAP.##plugins.themes.bootstrap3.article.details##
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.
References
Дзюблик Я.О. Раціональна антибіотикотерапія хворих на негоспітальну пневмонію III клінічної групи / Я.О. Дзюблик // Український пульмонологічний журнал. – 2014. – № 2. – С. 56–59.
Лапач С.Н. Статистические методы в медико-биологических исследованиях с использованием Exсel / С.Н. Лапач, А.В. Губенко, П. Н. Бабич. – К.: Морион, 2000. – 320 с. – ISBN 966-7632-16-4. МедиаСфера, 2002. – 312 с.
Перцева Т.А. Современный взгляд на фармакотерапию инфекций нижних дыхательных путей: место макролидов / Т.А. Перцева, Т.В. Киреева, М.А. Крыхтина // Український пульмонологічний журнал – 2015. – № 3. – С. 49–55.
Про затвердження клінічних протоколів надання медичної допомоги за спеціальністю «Пульмонологія» : Наказ МОЗ України № 128 від 19.03.2007 р. – Київ, 2007. – C. 146. http://old.moz.gov.ua/ua/portal/dn_20070319_128.html
Реброва О.Ю. Статистический анализ медицинских данных. Применение пакета прикладних программ STATISTICA / О.Ю. Реброва. – М.: МедиаСфера, 2002. – 312 с.
Antibiotic therapy for adults hospitalized with community-acquired pneumonia: a systematic review / J.S. Lee, D.L. Giesler, W.F. Gellad et al. // JAMA. – 2016. – Vol. 315. – Р. 593–602. https://doi.org/10.1001/jama.2016.0115
Antimicrobial resistance among respiratory Haemophilus influenzae isolates from pulmonology services over a six-year period / T.H. Geelen et al. // Scandinavian Journal of Infectious Diseases. – 2013. – Vol. 45 (8). – P. 606–611. https://doi.org/10.3109/00365548.2013.796088
Azithromycin: mechanisms of action and their relevance for clinical applications / M.J. Parnham, V. Erakovic Haber, E.J. Giamarellos-Bourboulis et al. // Pharmacological Therapy. – 2014. – Vol. 143. – P. 225–245. https://doi.org/10.1016/j.pharmthera.2014.03.003
Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. www.cdc.gov/drugresistance/threat-report-2013 Date last accessed: July 28, 2016. Date last updated: July 17, 2014.
Guidelines for the management of adult lower respiratory tract infections / M. Woodhead, F. Blasi, S. Ewig et al. // Clinical Microbiological Infection. – 2011. – Vol. 17 (6). – P. E1–E59. https://doi.org/10.1111/j.1469-0691.2011.03672.x
Mira J-P. The role of biomarkers in community-acquired pneumonia: predicting mortality and response to adjunctive therapy / J-P. Mira, P-R. Burgel // Critical Care. – 2008. – Vol. 12 – P. 1–7. https://doi.org/10.1186/cc7028
National Institute for Health and Care Excellence. Pneumonia in adults: diagnosis and management. NICE Guidance. https://www.nice.org.uk/guidance/cg191 Date last accessed: December 21, 2016. Date last updated: December, 2014.
Niederman M. S. Macrolide-Resistant Pneumococcus in Community-acquired Pneumonia. Is There Still a Role for Macrolide Therapy? / M.S. Niederman // American Journal of Respiratory Critical Care Medicine. – 2015. – P. 191–216. https://doi.org/10.1164/rccm.201504-0701ED
Patrick G.P. SMART-COP: A Tool for Predicting the Need for Intensive Respiratory or Vasopressor Support in Community-Acquired Pneumonia / G.P. Patrick Charles, R. Wolfe, M. Whitby // Clinical Infectious Diseases. – 2008. – Vol. 47 (3) – P. 375–384. https://doi.org/10.1086/589754
